SiSaf Ltd, an RNA therapeutics company, is pleased to announce the publication in the peer-reviewed journal Molecular Therapy Nucleic Acids(1) of positive in vivo data demonstrating the safety and efficacy of its siRNA therapy for Autosomal Dominant Osteopetrosis 2 (ADO2). The data reported in the paper demonstrate .
Peer-Reviewed Publication of Positive Preclinical Data of SiSaf s SIS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
SiSaf Ltd, an RNA delivery and therapeutics company, is pleased to announce positive data confirming safety and efficacy of its Bio-Courier™ next generation silicon stabilized hybrid lipid nanoparticles (sshLNP) as an effective non-viral delivery system for Autosomal Dominant Osteopetrosis 2 (ADO2) siRNA .
Data presented by academic collaborator from the University of L'Aquila, Italy at the American Society of Bone and Mineral Research (ASBMR) 2022 Annual Meeting, 9-12 September, Austin, Texas
/PRNewswire/ SiSaf Ltd, a company developing RNA therapeutics for rare genetic skeletal disorders, today announced that it has exercised its option under.